Leber Hereditary Optic Neuropathy (LHON)
A rare inherited condition that causes vision loss by damaging the retinal ganglion cells and optic nerve, the pathway that carries visual information from the eye to the brain.
Unlike inherited retinal diseases (IRDs), which primarily affect the retina’s light-sensing cells, LHON is an inherited optic neuropathy.
Understanding Leber Hereditary Optic Neuropathy
Leber Hereditary Optic Neuropathy (LHON) is a rare inherited condition that causes vision loss by damaging the retinal ganglion cells and optic nerve, the pathway that carries visual information from the eye to the brain.
Unlike inherited retinal diseases (IRDs), which primarily affect the retina’s light-sensing cells, LHON is an inherited optic neuropathy. It affects cells that transmit visual information from the retina to the brain and typically causes sudden, painless loss of central vision, often beginning in one eye and affecting the other eye within weeks or months.
LHON most commonly affects young adult males, although people of any sex can carry the genetic changes that cause the condition and may experience vision loss.
Advances in mitochondrial genetics, diagnosis, and gene-based therapies have increased understanding of LHON and created new opportunities for treatment and research.
Retina International works with people affected by LHON, patient organisations, researchers, clinicians, and partners worldwide to improve awareness, support patient involvement, and advance research into inherited vision conditions.


What is Leber Hereditary Optic Neuropathy?
Leber Hereditary Optic Neuropathy is an inherited optic neuropathy that causes degeneration of the retinal ganglion cells and optic nerve.
The optic nerve contains millions of nerve fibres that transmit visual signals from the eye to the brain. When these cells become damaged, the brain cannot receive complete visual information, resulting in vision loss.
LHON primarily affects the retinal ganglion cells, particularly those involved in central vision. Because of this, LHON is not considered an inherited retinal dystrophy (IRD), even though the affected cells are located within the retina.
The condition typically presents with:
· Sudden loss of central vision
· Reduced ability to see fine details
· Difficulty reading and recognising faces
· A central or central-to-peripheral blind spot
Peripheral vision is often preserved, although some people may experience broader visual changes.
LHON is a mitochondrial disease, meaning it is caused by changes in mitochondrial DNA (mtDNA), which affects how cells produce energy.
The condition is sometimes referred to as:
· Leber optic neuropathy
· Leber hereditary optic atrophy
1 in 30,000–50,000
Estimated prevalence in Northern Europe
~90%
Of cases are linked to three main genetic changes
97%
Typically develop vision loss in both eyes within one year
How LHON can affect vision
Blurred central vision
People may notice difficulty focusing on objects directly in front of them.
Loss of central vision
A blind spot may develop in the centre of vision, affecting:
· Reading
· Recognising faces
· Watching television
· Detailed tasks
Reduced colour vision
Some people experience reduced ability to distinguish colours.
Reduced visual sharpness
Central vision may become significantly impaired.
Vision loss in both eyes
LHON often affects one eye first, followed by the second eye within a period of weeks or months.
The severity of vision loss varies between individuals.
Some people experience partial recovery, while others have long-term significant central vision impairment.
Identifying LHON
Eye examination
An ophthalmologist examines the optic nerve and evaluates visual function.
Visual field testing
This measures areas of vision loss and helps identify central visual field defects.
Optical coherence tomography (OCT)
OCT can assess changes in the retinal nerve fibre layer and retinal ganglion cells.
Colour vision testing
This evaluates changes in colour perception.
Genetic testing
Genetic testing of mitochondrial DNA can identify LHON-associated mutations.
A genetic diagnosis can help:
- · Confirm the condition
- · Distinguish LHON from other causes of optic nerve damage
- · Support family counselling
- · Identify eligibility for clinical research
Supporting vision and exploring treatment options
Approved treatments
Some individuals may benefit from approved therapies designed to support mitochondrial function and visual outcomes. Treatment decisions should always be discussed with a specialist.
Low vision support
People living with LHON may benefit from:
· Magnification devices
· Screen readers
· Accessibility technology
· Orientation and mobility support
Lifestyle considerations
Because certain factors may influence whether vision loss develops, individuals with LHON may be advised to discuss:
· Smoking cessation
· Alcohol consumption
· General health management
with their healthcare provider.
Genetic counselling
Genetic counselling can help individuals and families understand:
· Mitochondrial inheritance
· Family risks
· Testing options
Emerging therapies
Research continues into:
· Gene therapy
· Mitochondrial-targeted treatments
· Neuroprotective approaches
Adapting to sudden vision loss
Unlike many inherited retinal diseases, LHON often begins suddenly, meaning people may need to adapt quickly to significant changes in vision.
The impact may affect:
- Education
- Employment
- Mobility
- Independence
- Emotional wellbeing
Support may include:
- Low vision rehabilitation
- Assistive technology
- Workplace and educational accommodations
- Peer support
- Patient organisations
Early access to practical and emotional support can help people adapt and maintain independence.
The experiences of people living with LHON are important in shaping research, healthcare services, and advocacy priorities.

Advancing the future of LHON treatment
Gene therapy
Researchers are exploring approaches that introduce functional genetic material to affected retinal ganglion cells.
Learn About Gene TherapyMitochondrial therapies
Scientists are investigating ways to improve mitochondrial energy production and protect vulnerable retinal ganglion cells.
Learn About Mitochondrial therapiesNatural history studies and registries
Long-term studies help researchers understand disease progression and identify meaningful outcomes for clinical trials.
Learn About Natural History StudiesClinical trials
Clinical studies continue to investigate potential therapies aimed at improving visual outcomes for people affected by LHON.
Learn About Clinical TrialsPatient involvement in research
People living with LHON contribute essential insights into:
- Meaningful treatment outcomes
- Quality-of-life impacts
- Clinical trial design
Information and community support
Take the Next Step
Leber Hereditary Optic Neuropathy highlights the importance of genetic understanding, mitochondrial research, and patient-centred innovation in advancing treatments for inherited vision conditions.
Although LHON is inherited, it is not an inherited retinal dystrophy (IRD). It is an inherited optic neuropathy that primarily affects retinal ganglion cells and the optic nerve.
Through collaboration between patients, researchers, clinicians, and organisations worldwide, progress continues towards improved diagnosis, stronger support, and new therapies that may preserve or restore vision.